Author + information
- Received July 2, 2009
- Accepted August 16, 2009
- Published online April 13, 2010.
- Peter Panizzi, PhD⁎,‡,
- Filip K. Swirski, PhD⁎,‡,
- Jose-Luiz Figueiredo, MD⁎,‡,
- Peter Waterman, BS⁎,‡,
- David E. Sosnovik, MD†,‡,
- Elena Aikawa, MD, PhD‡,
- Peter Libby, MD§,
- Mikael Pittet, PhD⁎,
- Ralph Weissleder, MD, PhD⁎,‡,⁎ ( and )
- Matthias Nahrendorf, MD, PhD⁎,‡,⁎ ()
- ↵⁎Reprint requests and correspondence:
Drs. Ralph Weissleder or Matthias Nahrendorf, Center for Systems Biology, 185 Cambridge Street, Boston, Massachusetts 02114
Objectives The aim of this study was to test whether blood monocytosis in mice with atherosclerosis affects infarct healing.
Background Monocytes are cellular protagonists of tissue repair, and their specific subtypes regulate the healing program after myocardial infarction (MI). Inflammatory Ly-6Chimonocytes dominate on Day 1 to Day 4 and digest damaged tissue; reparative Ly-6Clomonocytes dominate on Day 5 to Day 10 and promote angiogenesis and scar formation. However, the monocyte repertoire is disturbed in atherosclerotic mice: Ly-6Chimonocytes expand selectively, which might disrupt the resolution of inflammation.
Methods Ex vivo analysis of infarcts included flow cytometric monocyte enumeration, immunoactive staining, and quantitative polymerase chain reaction. To relate inflammatory activity to left ventricular remodeling, we used a combination of noninvasive fluorescence molecular tomography (FMT-CT) and physiologic imaging (magnetic resonance imaging).
Results Five-day-old infarcts showed >10× more Ly-6Chimonocytes in atherosclerotic (apoE−/−) mice compared with wild-type mice. The injured tissue in apoE−/−mice also showed a more pronounced inflammatory gene expression profile (e.g., increased tumor necrosis factor-alpha and myeloperoxidase and decreased transforming growth factor-beta) and a higher abundance of proteases, which are associated with the activity of Ly-6Chimonocytes. The FMT-CT on Day 5 after MI showed higher proteolysis and phagocytosis in infarcts of atherosclerotic mice. Serial magnetic resonance imaging showed accelerated deterioration of ejection fraction between Day 1 and Day 21 after MI in apoE−/−. Finally, we could recapitulate these features in wild-type mice with artificially induced Ly-6Chimonocytosis.
Conclusions Ly-6Chimonocytosis disturbs resolution of inflammation in murine infarcts and consequently enhances left ventricular remodeling. These findings position monocyte subsets as potential therapeutic targets to augment tissue repair after infarction and to prevent post-MI heart failure.
In the first week after coronary occlusion, the myocardium experiences high cell and extracellular matrix turnover (1–4) and is exposed to the constant stress of cycling intracardiac pressures. The quality of infarct healing determines the mechanical properties of the injured tissue and therefore prognosis: poor healing might lead to infarct rupture or left ventricular dilation due to infarct expansion (5). Timely reperfusion therapy reduces acute infarct mortality (6), and current standard of care attenuates post-myocardial infarction remodeling (7,8). However, present therapies typically have modest long-term effects: for example, the SAVE trial indicated that angiotensin-converting enzyme inhibitors can only reduce infarct mortality from 25% to 20% (9); and mortality remains even higher in patients with end-stage heart failure (10). Thus, there is a need to better understand the complex cellular and molecular constituents that regulate myocardial healing and remodeling, because they might serve as biomarkers and therapeutic targets for the prediction and prevention of heart failure.
Recruitment of monocytes from the bloodstream into the vessel wall drives atherosclerotic plaque growth and vulnerability (11). Blood levels of inflammatory Ly-6Chimonocytes increase profoundly in atherosclerotic mice (12,13), and peripheral monocytosis occurs in patients with coronary artery disease (14,15). At the same time, Ly-6Chimonocytes dominate in the myocardial wound on Day 1 to Day 4 after coronary ligation and digest necrotic tissue (monocytic Phase 1) (16). During a second monocytic phase that ensues directly (Phase 2), the number of Ly-6Chimonocytes declines rapidly while reparative Ly-6Clomonocytes accumulate and propagate healing and the resolution of inflammation. Abrogation of either monocytic phase results in poor healing, indicating that successful cardiac wound repair depends on a well-coordinated bi-phasic monocyte response (16). The present study tested the hypothesis that atherosclerosis-associated Ly-6Chiblood monocytosis interferes with resolution of inflammation during the monocytic Phase 2 of infarct healing. We hypothesized that, on the basis of clinical data showing that blood monocytosis independently associates with heart failure after MI (17,18), pre-existing blood monocytosis in atherosclerotic mice increases and prolongs the presence of Ly-6Chimonocytes in the infarct, interferes with resolution of inflammation after ischemic injury, enhances LV remodeling, and thus ultimately favors heart failure. This hypothesis has considerable clinical relevance, because inflammation predisposes to complications of atherosclerosis such as acute MI (11).
Although inflammation is typically assessed with ex vivo techniques, noninvasive tools that gauge inflammation can be used to relate innate immune cell function in the infarct with ventricular dilation and subsequent development of heart failure. Here we used fluorescence molecular tomography in conjunction with anatomical computed tomography (FMT-CT) and magnetic resonance imaging for in vivo assessment of cellular responses and physiological consequences otherwise hard to measure longitudinally.
C57B/6 and apolipoprotein E knockout (apoE−/−) mice were purchased from Jackson Laboratories (Bar Harbor, Maine). ApoE−/−mice had an average age of 45 weeks and were on a high-cholesterol diet (0.2% total cholesterol) (Harlan Teklad, Madison, Wisconsin). An MI was induced by coronary ligation as described before (19). We first conducted an invasive study that assessed monocyte numbers and the quality of inflammation and healing by flow cytometric and molecular profiling of infarcts harvested on Day 5 after MI. We next investigated the interrelation of infarct healing and ventricular dilation in a longitudinal trial with serial MRI on Day 1 and Day 21 and FMT-CT imaging on Day 5 after MI. To study the impact of blood monocytosis on infarct healing in a model independent of lipid metabolism, we induced blood monocytosis in C57B/6 mice (50 μg of lipopolysaccharide [Sigma, St. Louis, Missouri] IP injections  24 h before and on Days 1, 2, 3, and 4 after MI). The contribution of neutrophils to healing in apoE−/−mice was assessed in a cohort in which we depleted neutrophils (500 mg IP injections of anti Ly-6G antibody [BioXCell, West Lebanon, New Hampshire] 24 h before and on Day 1 and Day 3 after MI). The experimental protocol and animal numbers are outlined in Figure 1.The local institutional animal welfare committee approved the research reported.
On Day 5 after MI, peripheral blood and infarct tissue were prepared for flow cytometric quantitation of leukocytes as described before (16). Cell suspensions were incubated with a cocktail of monoclonal antibodies against T cells (CD90-PE, 53-2.1), B cells (B220-PE, RA3-6B2), NK cells (CD49b-PE, DX5 and NK1.1-PE, PK136), granulocytes (Ly-6G-PE, 1A8), myeloid cells (CD11b-APC, M1/70), antigen-presenting cells (I-Ab(AF6-120.1)-biotin-Strep-PerCP), and monocyte subsets (Ly-6C-FITC, AL-21) (BD Biosciences, San Jose, California). Monocytes were identified as CD11bhi(CD90/B220/CD49b/NK1.1/Ly-6G)lo(F4/80/I-Ab/CD11c)loLy-6Chi/lo. Macrophages/dendritic cells were identified as CD11bhi(CD90/B220/CD49b/NK1.1/Ly-6G)lo(I-Ab/CD11c)hiLy-6Clo. Neutrophils were identified as CD11bhi(CD90/B220/CD49b/NK1.1/Ly-6G)hi(I-Ab/CD11c)loLy-6Cint. Monocyte and macrophage cell numbers were calculated as total cells multiplied by percent cells within the monocyte/macrophage gate. Within this population, monocyte subsets were identified as (I-Ab/CD11c)loand either Ly-6Chior Ly-6Clo. For assessment of proteolytic activity including cathepsins, 5 nmol Prosense-680 (VisEn Medical, Bedford, Massachusetts) was injected into the tail vein 24 h before the animal was killed. For assessment of phagocytic activity, CLIO-VT750 (Center for Molecular Imaging Research Chemistry Core, Boston, Massachusetts), 15 mg of iron/kg bodyweight (21), was injected into the tail vein 24 h before the animal was killed. Data were acquired on an LSRII (BD Biosciences).
Serial 6 μm-thick sections were stained for neovessels (CD31, BD Pharmingen, San Diego, California), vascular endothelial growth factor (VEGF) (Abcam, Cambridge, United Kingdom), proteases (cathepsin B [Santa Cruz Biotechnology, Santa Cruz, California] and matrix metalloproteinase [MMP]-2 and MMP-9 [Millipore, Billerica, Massachusetts]), and macrophages (F4/80, Abcam). We quantified the percentage positive area within the field of view with 5 high-power fields (magnification ×200) per section and per animal.
Fluorescence Reflectance Imaging
On Day 5 after MI, short-axis rings were imaged at 4× magnification (OV-110, Olympus, Center Valley, Pennsylvania) in the 680 nm and 750 nm channels 24 h after injection of Prosense-680 and CLIO-750.
Quantitative Polymerase Chain Reaction
Multiplex quantitative polymerase chain reaction was performed on triplicate samples with Applied Biosystems (Foster City, California) TaqMan assays. Infarct tissue was examined for expression of markers of inflammatory monocytes (Ly-6C, Mm00841873_m1), differentiated macrophages (CD68, Mm00839636_g1; Mac3, Mn00495267_m1), tumor necrosis factor-alpha (Mm00443258-m1), myeloperoxidase (MPO) (Mm00447886_m1), transforming growth factor-beta (Mm00436971_m1), and appropriate controls (glyceraldehyde-3-phosphate dehydrogenase, apoE).
To evaluate the prognostic significance of ex vivo findings, we assessed monocyte-associated biomarkers in the infarct and followed, in parallel, LV remodeling in the same cohort of mice. This approach used FMT-CT as a molecular imaging tool and MRI to quantitate physiological variables, a powerful and effective combination to follow the events after MI longitudinally.
To validate the FMT-CT fusion algorithm, we used a tissue phantom filled with a solution of 30 μl CT contrast (Isovue-370, Bracco, Princeton, New Jersey) and 1 nmol of the fluorochrome VT-680 (VisEn Medical). With an FMT 2500 system (VisEn Medical), we acquired 30 frontal slices of 0.5 mm thickness in the z-direction, with an in-plane resolution of 1 × 1 mm. Data were post-processed with a normalized Born forward equation to calculate 3-dimensional fluorochrome concentration maps. The phantom was then imaged by CT while positioned in a multimodality cartridge.
On Day 5 after MI, 1 day after onset of the monocytic Phase 2 (16), we performed dual channel (680/700 nm and 750/800 nm excitation/emission) FMT-CT imaging to interrogate the magnitude and quality of inflammation 24 h after injection of 5 nmol of a pan-cathepsin protease sensor (Prosense-680) and 15 mg/kg body weight CLIO-750, nanoparticles prone to be ingested by phagocytes (21). A 3D dataset was reconstructed in which fluorescence/voxel was expressed in nmol/l. To robustly identify the region of interest in the heart, anatomic imaging with CT immediately followed FMT. The imaging cartridge containing the anesthetized mouse was placed into the custom-machined Plexiglas holder that supplies isoflurane, warm air, and optimal positioning in the CT (Inveon PET-CT, Siemens, Malvern, Pennsylvania). The CT X-ray source operated at 80 kVp and 500 μA with an exposure time of 370 to 400 ms. The effective 3D resolution was 80 μm isotropic. Isovue-370 was infused intravenously at 55 μl/min through a tail-vein catheter. The CT reconstruction protocol performed bilinear interpolation, used a Shepp-Logan filter, and scaled pixels to Hounsfield units.
The fusion method realized 3D mapping of fluorescence within the anatomical reference CT. The approach was based on a multimodality-compatible animal-holding device that provides fiducial landmarks on its frame. The imaging cartridge lightly compressed the anesthetized mouse between optically translucent windows and thereby prevented motion during transfer between modalities. The 3D distribution of the fiducial landmarks enabled co-registration of datasets in an automated fashion. The point-based coregistration tool kit in OsiriX shareware fused images after identification of fiducial landmarks in respective modalities. Fiducial landmarks were tagged with point markers to define their XYZ coordinates. With these coordinates, data were resampled, rotated, and translated to match the image matrices and finally fused.
We performed in vivo MRI on Day 1 and Day 21 after MI in the same mice that were imaged by FMT-CT to follow the functional impact of infarct healing on the evolution of heart failure. A 7-T horizontal-bore Pharmascan (Bruker, Billerica, Massachusetts) was used to obtain hyperenhancement cine images of the LV short axis after injection of gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) (Berlex, Wayne, New Jersey) at a dosage of 0.3 mmol/kg (22). We employed ECG and respiratory gating with a T1-weighted gradient echo sequence (echo time 2.7 ms, 16 frames/RR interval; flip angle 60°; in-plane resolution 200 × 200 μm; slice thickness 1 mm). Cardiac volumes were quantitated from 6 to 8 short-axis imaging slices covering the LV. The infarcted area was identified in end-diastolic frames as: 1) hypokinetic in cine-loops, and 2) hyperenhancing after Gd-DTPA injection. Changes of parameters over time were then calculated (i.e., Delta end-diastolic volume [EDV] = EDVday21− EDVday1).
Results are expressed as mean ± SEM. Statistical comparisons between 2 groups were evaluated by Student ttest. A p value <0.05 was considered statistically significant. No corrections were made for multiple comparisons.
We first investigated whether elevated blood levels of inflammatory Ly-6Chimonocytes in atherosclerotic apoE−/−mice (12) (corroborated in the present study, Fig. 2)result in increased and prolonged presence of these cells in the healing infarct. We collected infarcts on Day 5, because this time point represents the start of Phase 2 (i.e., the healing phase dominated by anti-inflammatory Ly-6Clomonocytes in wild-type mice) (16). Although the number of Ly-6Chimonocytes in wild-type mice had already declined (1.1 ± 0.1 × 104cells in heart), we found >10× more Ly-6Chicells in infarcts of apoE−/−mice (14.4 ± 5.8 × 104cells, p < 0.05) (Fig. 2). The ratio of Ly-6Chito Ly-6Cloin infarct tissue was 1.2 for wild-type and 2.2 for apoE−/−mice. ApoE−/−mice also showed higher numbers of neutrophils and macrophages (Fig. 2); the latter likely derive from Ly-6Chimonocytes (12).
Monocyte subsets exhibit functional heterogeneity, and Ly-6Chimonocytes selectively show higher inflammatory activity (23). Thus, we investigated the inflammatory status of infarct tissue by immunohistochemistry and gene expression analysis. Quantitative staining showed increased cathepsin B (target enzyme of the fluorescent protease imaging sensor), MMP-2, and MMP-9 enzymes in infarcts of apoE−/−compared with wild-type mice (Fig. 3A).The number of CD31+microvessels was higher in apoE−/−mice, likely due to higher inflammatory cell numbers that shuttle in proteases and VEGF (Fig. 3A). Interestingly, MMP9 has been reported to promote VEGF release in cancer (24). mRNA levels of the inflammatory enzyme MPO and TNF-alpha increased in apoE−/−infarct tissue, whereas mRNA levels of TGF-beta—a protein that stimulates fibroblast function and collagen deposition to strengthen the evolving infarct scar (1–4)—declined (Fig. 3B). PCR confirmed increased levels of Ly-6C (monocytes) and CD68 and MAC-3 (macrophages) (Fig. 3B). We also compared monocyte subsets directly for proteolysis and phagocytosis. This involved IV injection of an activatable pan-cathepsin sensor (Prosense-680) and a phagocytosis sensor (CLIO-750), followed by flow cytometry analysis of cell suspensions isolated from infarcts. Ly-6Chimonocytes showed 7.5-fold more protease activity than their Ly-6Clocounterparts in vivo, whereas both subsets had similar phagocytic activity (Table 1).Both activities were lower in CD11b−cells (mostly T and B cells) and neutrophils (Table 1). These data indicate that the prolonged Phase I Ly-6Chimonocyte response in infarcts of apoE−/−mice associates with heightened inflammatory activity.
The above results indicate that the activatable pan-cathepsin sensor should report selectively on Ly-6Chimonocytes in vivo, whereas the phagocytosis sensor indicates the presence of both monocyte subsets. Thus, we thought to use these agents in combination with fusion FMT-CT imaging to map the monocyte response in infarct tissues in vivo (FMT detects molecular signal, whereas CT gives anatomical information). Initially, we performed phantom validation experiments to evaluate the accuracy of fusion of datasets obtained from the 2 imaging modalities. Phantoms placed in a multimodality mouse holder (Fig. 4A)underwent imaging with both modalities. Fusion was performed with fiducial landmarks on the holder frame (Figs. 4B to 4D). We then measured the distance between the phantom cavity, which was filled with a CT contrast/fluorochrome solution, and the edge of the phantom on CT images (Fig. 4B). The same measurement was repeated on the fused FMT-CT dataset, but here the cavity was identified using the fluorescence signal. We observed excellent spatial coregistration and correlation (R2= 0.994, p < 0.001) (Figs. 4D and 4E). Next, we evaluated a wild-type mouse after coronary ligation injected with CLIO-750 to report on phagocytic activity. CT allowed assessment of anatomy, whereas FMT-CT fusion showed the fluorescence signal localized in the left side of the thoracic cavity, a finding that was consistent with uptake into the infarct region (Figs. 4F to 4K). We then investigated in vivo cathepsin and phagocytic activities in infarcts of apoE−/−mice during monocytic healing Phase 2, when the protease activity has passed its peak (21) and the number of Ly-6Chimonocytes has declined in infarcts of wild-type mice (16). We first assessed infarct size by delayed enhancement MRI, as outlined in the serial imaging protocol (Fig. 1), which showed no significant difference between groups (wild-type 16 ± 3%, apoE−/−14 ± 2%, p = 0.6). In some apoE−/−mice, CT showed vascular calcification in the aortic wall coincident with atherosclerotic plaques. Two-dimensional and 3D reconstructions of fused FMT-CT images showed Prosense-680 and CLIO-750 signals in the apex of the LV. Corresponding to the increase of Ly-6Chi monocytes and macrophages by flow cytometry, histology, and PCR data, we found higher protease and phagocytic activity in infarcts of apoE–/–mice (p < 0.05) (Fig. 5A).Ex vivo reflectance fluorescence imaging of myocardial rings harvested from a separate group of mice corroborated our in vivo FMT findings. The target-to-background ratio for both molecular probes was higher in the infarct of apoE−/−mice when compared with wild-type mice (p < 0.0001) (Fig. 5B). Ex vivo, Prosense-680 signal was 2.7-fold and CLIO-750 signal 3.3-fold higher in apoE−/−infarcts when compared with wild-type mice, similar to the differences seen in vivo (FMT for Prosense-680 and CLIO-750: 2.9- and 2.6-fold increase in apoE−/−mice, respectively). Of note, the fluorescence of infarcts in wild-type mice, although lower than that in apoE−/−animals, significantly exceeded the signals in sham-operated control subjects that received the molecular sensors without coronary artery ligation (p < 0.0001).
We next quantitated LV remodeling with serial cine MRI. We observed similar myocardial hypertrophy in wild-type and apoE−/−mice (Fig. 6).Although ejection fraction was comparable between groups on Day 1 after MI, enhanced ventricular dilation of the LV tripled its decline between Day 1 and Day 21 in apoE−/−mice. The MRI-derived increase in end-diastolic volume positively correlated with protease activity measured with FMT (Prosense-680 activation, R2= 0.39, p = 0.003) but not with phagocytic activity (CLIO-750 uptake, p = 0.24). The correlation of FMT-derived protease signal with LV dilation implies that: 1) protease sensing can predict post-MI heart failure; and 2) prolonged retention of proteolytic Ly-6Chimonocytes impairs infarct healing and ventricular remodeling. Heart and body weights were comparable in wild-type and apoE−/−mice (Table 2).
Phenotypic changes in apoE−/−mice with high-cholesterol diet might not be limited to the change in monocyte subsets. Thus, we thought to investigate whether Ly-6Chimonocytosis is causally linked to LV remodeling. To this end, we investigated an independent mouse model in which monocytosis is not related to germline deletion of apoE and hyperlipidemia but is induced experimentally in wild-type mice by repeated injections of lipopolysaccaride (LPS) (20). Flow cytometry on Day 5 after MI showed increased numbers of monocytes in blood and in infarcts, comparable to our observations in apoE−/−mice (Fig. 7A).FMT-CT showed increased protease and phagocytic signal, and MRI showed increased ventricular dilation in LPS-treated mice in vivo (Fig. 7A). Thus, increased inflammation in infarct tissue and subsequent heart failure are both recapitulated in wild-type mice with artificially induced monocytosis. Of note, the LPS treatment did not alter the recruitment of neutrophils, which represent another important cellular mediator of inflammation after MI (Fig 7A). Also, in vivo depletion of neutrophils in apoE−/−mice did not restore post-MI remodeling (Fig 7B). These data indicate that the number of Ly-6Chimonocytes recruited into the infarct has direct consequences on LV remodeling.
Monocyte/macrophages contribute centrally to wound healing. Their known functions include removal of necrotic debris, propagation of angiogenesis, and regulation of extracellular matrix turnover (23,25). These phagocytes elaborate regulatory cytokines, chemokines, and proteolytic enzymes, all of which participate in tissue repair (1–4). Experimental (16,26) and clinical data (27) show that abrogation of monocytes compromises infarct healing. However, little is known about the downregulation of innate immune cell activity and associated inflammation after the initial burst triggered by ischemic myocardial injury. Here we show that effective infarct healing necessitates timely and coordinated resolution of inflammation. The endogenous repair response that follows MI requires immune cell populations that are profoundly altered during atherosclerosis, the condition that causes MI in most patients. Specifically, we found that Ly-6Chimonocytes, which are chronically expanded in the blood pool of atherosclerotic apoE−/−mice, impair infarct healing through prolonged presence in the infarct, delayed onset of monocytic Phase 2, and deregulated resolution of inflammation.
The increased circulating pool of Ly-6Chimonocytes in apoE−/−mice corresponded to a higher number of this inflammatory subset lingering in the infarct 5 days after MI, presumably because an excess of these cells in the circulation leads to their more abundant recruitment. The gene expression profile of apoE−/−infarcts remained pro-inflammatory when inflammation was already waning in wild-type infarcts. For instance, MPO activity peaks 2 days after MI in wild-type mice and quickly resolves thereafter (28). In the current study, we found that MPO transcription was still >3-fold higher in apoE−/−infarcts on Day 5. Therefore, we speculate that the increased residual Ly-6Chimonocytes in the myocardial infarcts of apoE−/−mice hampered transition toward an anti-inflammatory healing microenvironment. Future studies will need to determine the precise mechanisms responsible for elevated Ly-6Chimonocyte presence in the myocardium of these mice. Notably, hypercholesterolemia has been shown to promote monocyte proliferation and survival (12) and might therefore modulate Phase I to Phase II transition. However, LPS-induced monocytosis also resulted in sustained infarct inflammation and accelerated ventricular dilation, suggesting that blood monocytosis might hamper resolution of inflammation in the infarct. Furthermore, although neutrophil depletion did not improve remodeling in apoE−/−mice, the role of the prolonged presence of these cells requires further study.
The use of noninvasive molecular and physiological imaging (29) allowed us to correlate the inflammatory milieu in the infarct (30) in vivo with the development of heart failure. Infarcts of apoE−/−mice had higher protease activity and increased phagocytic rates compared with those in wild-type mice. Flow cytometric probe distribution studies suggested that this constellation is caused by a high number of Ly-6Chimonocytes in apoE−/−infarcts, because the inflammatory subset activates more protease sensor moieties per monocyte. Consequently, ventricular dilation was accelerated and resulted in a 16% lower ejection fraction 3 weeks after MI in apoE−/−mice. Cathepsin activity, by virtue of its association with Ly-6Chimonocytes, is an integral component of the early monocytic phase of myocardial repair. The positive correlation between enzyme activity and LV dilation suggests that a prolonged Phase I or a compromised Phase II predisposes to heart failure. Translation of this diagnostic concept might permit identification of infarct patients at accentuated risk for developing heart failure.
The results of our study point to inflammatory monocytes as a potential therapeutic target in post-MI heart failure, whose modulation might augment healing and attenuate LV remodeling. Future work should search for measures to support the Ly-6Chi→ Ly-6Closubset recruitment switch and to chaperone the healing microenvironment toward dampened inflammation during the second monocytic phase. Molecular imaging that interrogates monocytic targets in injured myocardium in conjunction with quantitation of monocyte subsets in the circulation might provide prognostic information and help guide therapies to promote favorable ventricular remodeling after MI.
The authors acknowledge help from members of the Mouse Imaging Program (MIP), Anne Yu, BS, Alexandra Kunin, BS, Elisabeth Zhang, BS, and Brett Marinelli, BS, for help with imaging and data processing; Yoshiko Iwamoto, BS, for histological staining, and Nikolai Sergeyev, PhD, for nanoparticle synthesis. Wael Yared, PhD, and Thorsten Mempel, PhD, are acknowledged for helpful discussions.
This work was funded in part by National Institutes of Health grantsto Dr. Weissleder (UO1-HL-080731, RO1-EB006432, T32-CA79443, R24-CA92782, P50-CA86355) and Dr. Nahrendorf (R01HL096576) and an American Heart Associationgrant (0835623D) to Dr. Nahrendorf. Dr. Weissleder and Mr. Waterman own shares of VisEn Medical.
- Abbreviations and Acronyms
- apolipoprotein E knockout
- computed tomography
- end-diastolic volume
- fluorescence molecular tomography X-ray computed tomography
- gadolinium-diethylenetriaminepentaacetic acid
- left ventricle/ventricular
- myocardial infarction
- matrix metalloproteinase
- magnetic resonance imaging
- vascular endothelial growth factor
- Received July 2, 2009.
- Accepted August 16, 2009.
- American College of Cardiology Foundation
- Frangogiannis N.G.,
- Entman M.L.
- Cleutjens J.P.,
- Blankesteijn W.M.,
- Daemen M.J.,
- Smits J.F.
- Ertl G.,
- Frantz S.
- Sutton M.G.,
- Sharpe N.
- Lee K.L.,
- Woodlief L.H.,
- Topol E.J.,
- et al.
- Latini R.,
- Tognoni G.,
- Maggioni A.P.,
- et al.,
- Angiotensin-Converting Enzyme Inhibitor Myocardial Infarction Collaborative Group
- Pfeffer M.A.,
- Braunwald E.,
- Moye L.A.,
- et al.,
- The SAVE Investigators
- ↵NHLBI Financial Year 2008 Fact Book. http://www.nhlbigov/about/factbook/tochtm. Accessed March 22, 2010.
- Nahrendorf M.,
- Swirski F.K.,
- Aikawa E.,
- et al.
- Maekawa Y.,
- Anzai T.,
- Yoshikawa T.,
- et al.
- Mariani M.,
- Fetiveau R.,
- Rossetti E.,
- et al.
- Nahrendorf M.,
- Hu K.,
- Frantz S.,
- et al.
- O'Connell R.M.,
- Rao D.S.,
- Chaudhuri A.A.,
- et al.
- Nahrendorf M.,
- Sosnovik D.E.,
- Waterman P.,
- et al.
- Yang Z.,
- Berr S.S.,
- Gilson W.D.,
- Toufektsian M.C.,
- French B.A.
- Nahrendorf M.,
- Sosnovik D.,
- Chen J.W.,
- et al.
- Su H.,
- Spinale F.G.,
- Dobrucki L.W.,
- et al.